Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.55 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Income Statements
Fiscal Year end for Milestone Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 5 | 15 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 5 | 15 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 62 | 65 | 58 | 51 | 58 |
Income After Depreciation & Amortization | -61 | -60 | -43 | -51 | -58 |
Non-Operating Income | 4 | 1 | 0 | 1 | 3 |
Interest Expense | 3 | 0 | 0 | 0 | 0 |
Pretax Income | -60 | -58 | -43 | -50 | -55 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -60 | -58 | -43 | -50 | -55 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -60 | -58 | -43 | -50 | -55 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -61 | -60 | -43 | -51 | -58 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -61 | -60 | -43 | -51 | -58 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 42.96 | 42.45 | 41.83 | 29.35 | 15.79 |
Diluted EPS Before Non-Recurring Items | -1.39 | -1.38 | -1.02 | -1.70 | -3.50 |
Diluted Net EPS (GAAP) | -1.39 | -1.38 | -1.02 | -1.70 | -3.50 |
Fiscal Year end for Milestone Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 9.67 | 10.48 | 13.80 | 15.36 | 16.43 |
Income After SG&A, R&D, and Dept/Amort Expenses | -9.67 | -10.48 | -13.80 | -15.36 | -16.43 |
Non-Operating Income | 1.19 | 0.99 | 1.08 | 1.12 | 1.21 |
Interest Expense | 0.89 | 0.87 | 0.89 | 0.84 | 0.82 |
Pretax Income | -9.36 | -10.35 | -13.61 | -15.08 | -16.04 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.36 | -10.35 | -13.61 | -15.08 | -16.04 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -9.36 | -10.35 | -13.61 | -15.08 | -16.04 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 66.17 | 50.16 | 43.08 | 42.97 | 42.94 |
Diluted EPS Before Non-Recurring Items | -0.14 | -0.21 | -0.32 | -0.35 | -0.37 |
Diluted Net EPS (GAAP) | -0.14 | -0.21 | -0.32 | -0.35 | -0.37 |